Incanthera PLC - Further re: Director's Dealing
Announcement provided by
Incanthera plc · INC30/03/2023 07:00
30 March 2023
Incanthera plc
("Incanthera" or the "Company")
Further re: Director's Dealing
The Company advises that, further to its announcement of 13 March 2023, the investment of
Included in the initial application for Admission of the Investment Shares were 1,079,138 new ordinary shares, issued at the same price as the Investment Shares of
A further announcement will be made in due course on Admission of the Investment Shares.
Following Admission of the Fee Shares, the Company's enlarged issued share capital will comprise 77,464,166 ordinary shares of
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 (which forms part of domestic
For further enquiries:
Incanthera plc:
Tim McCarthy, Chairman tim.mccarthy@incanthera.com
Simon Ward, Chief Executive Officer simon.ward@incanthera.com
Suzanne Brocks, Head of Communications suzanne.brocks@incanthera.com |
+44 (0) 7831 675747
+44 (0) 7747 625506
+44 (0) 7776 234600 |
|
|
Aquis Exchange Corporate Adviser: Cairn Financial Advisers LLP Jo Turner/Ludo Lazzaretti |
+44 (0) 20 7213 0880 |
|
|
Broker: Stanford Capital Partners Ltd Patrick Claridge/Tom Price/John Howes/Bob Pountney |
+44 (0) 20 3650 3650 |
Notes to Editors
Incanthera is dedicated to innovative technologies in dermatology and oncology. It seeks to identify and commercialise inspirational therapeutics combined with uniquely targeted delivery systems, for innovative solutions to clinical, commercially relevant unmet needs.
The Company's current lead product and focus is Sol, a potentially innovative topical product for the treatment of solar keratosis and the prevention of skin cancers. The Company is currently focussed upon delivering Sol to a commercial partner.
Originating from the Institute of Cancer Therapeutics ("ICT") at the University of Bradford, the Company has acquired and developed a portfolio of specific cancer-targeting therapeutics, with a strategy to develop each candidate from initial acquisition/discovery to commercially valuable partnerships at the earliest opportunity in its development pathway.
For more information on the Company please visit: www.incanthera.com
@incantheraplc
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.